Android app on Google Play

Needham & Company Maintains Buy on Hyperion Therapeutics (HPTX) Post Q4

February 26, 2013 9:06 AM EST Send to a Friend
Get Alerts HPTX Hot Sheet
Price: $25.61 --0%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 9 | New: 6
Trade HPTX Now!
Join SI Premium – FREE
Needham & Company reiterated its Buy rating and $25 price target on Hyperion Therapeutics (NASDAQ: HPTX) following Q4 results.

The analyst reminds clients that Ravicti was approved on 2/1/13 for the treatment of Urea Cycle Disorders. Launch is still planned prior to the end of April 2013. The sales force has been hired and efforts are underway with payers around coverage, they said.

"We expect the company to continue discussions with the FDA in 2013 around the design of a Phase 3 program in Hepatic Encephalopathy (HE)," the analyst notes. "A trial is expected to begin by YE13"

For an analyst ratings summary and ratings history on Hyperion Therapeutics click here. For more ratings news on Hyperion Therapeutics click here.

Shares of Hyperion Therapeutics closed at $19.14 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Needham & Company

Add Your Comment